Literature DB >> 20595103

No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166.

Amy V Jones, Nicholas C P Cross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20595103      PMCID： PMC2895051          DOI： 10.3324/haematol.2010.023390

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease.

Authors:  Kai Wang; Haitao Zhang; Subra Kugathasan; Vito Annese; Jonathan P Bradfield; Richard K Russell; Patrick M A Sleiman; Marcin Imielinski; Joseph Glessner; Cuiping Hou; David C Wilson; Thomas Walters; Cecilia Kim; Edward C Frackelton; Paolo Lionetti; Arrigo Barabino; Johan Van Limbergen; Stephen Guthery; Lee Denson; David Piccoli; Mingyao Li; Marla Dubinsky; Mark Silverberg; Anne Griffiths; Struan F A Grant; Jack Satsangi; Robert Baldassano; Hakon Hakonarson
Journal:  Am J Hum Genet       Date:  2009-02-26       Impact factor: 11.025

2.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

3.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.

Authors:  Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmada; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephan R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; Jean-Pierre Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwilliam; Mark Tremelling; Panos Deloukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly
Journal:  Nat Genet       Date:  2008-06-29       Impact factor: 38.330

Review 4.  Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.

Authors:  S Brand
Journal:  Gut       Date:  2009-08       Impact factor: 23.059

5.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

6.  Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

Authors:  Amy V Jones; Richard T Silver; Katherine Waghorn; Claire Curtis; Sebastian Kreil; Katerina Zoi; Andreas Hochhaus; David Oscier; Georgia Metzgeroth; Eva Lengfelder; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

7.  Autoimmunity and the risk of myeloproliferative neoplasms.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2010-01-06       Impact factor: 9.941

8.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

9.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

10.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.

Authors: 
Journal:  Nature       Date:  2007-06-07       Impact factor: 49.962
View more
  2 in total

1.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

2.  An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer.

Authors:  Bríd M Ryan; Roger K Wolff; Nicola Valeri; Mohammed Khan; Dillon Robinson; Alessio Paone; Elise D Bowman; Abbie Lundgreen; Bette Caan; John Potter; Derek Brown; Carlo Croce; Martha L Slattery; Curtis C Harris
Journal:  Cancer Epidemiol       Date:  2014-08-15       Impact factor: 2.984
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.